Duarte, Calif.-based City of Hope researchers have developed a way to modify CAR-T cells after infusion, an approach designed to help the therapy adapt as tumors change.
The preclinical study on the technology was published Sept. 7 in Cancer Immunology Research.
The new platform relies on a molecular “docking system” that lets researchers attach add-on molecules to the cells, according to a Sept. 22 news release.
Those add-ons made the cells easier to monitor, supported their growth and broadened the types of cancer cells they could target. Existing CAR-T therapies are fixed once they reach the bloodstream. When tumors evolve to avoid detection, the therapy can stop working.
“The power of this platform is its flexibility,” co-senior author Christine Brown, PhD, deputy director of T Cell Therapeutics Research Laboratories at City of Hope, said in the news release.
Read the full study here.
